- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Value of Comprehensive Molecular Testing in NSCLC
Experts explore HER2 mutations and the critical role of comprehensive molecular profiling in optimizing treatment for non-small cell lung cancer patients.
In the first episode of this series, panelists discuss advancements in detecting HER2 mutations and the significance of comprehensive molecular profiling for non-small cell lung cancer (NSCLC). Experts describe that HER2 mutations, while relatively uncommon, are increasingly important as new targeted therapies emerge. The discussion emphasizes that HER2 testing should always be included in a broader multi-gene testing approach using next-generation sequencing (NGS) to optimize treatment planning. National guidelines recommend performing molecular profiling upfront for all patients with advanced or metastatic NSCLC—particularly those with non-squamous histology—using both tissue and plasma samples to maximize detection rates. The panel also compares real-world practices to guideline recommendations, noting that academic centers may more reliably implement comprehensive profiling, while some community settings face challenges with timely testing and access. Overall, the group underscores that timely and thorough molecular testing is essential to ensure patients benefit from evolving targeted therapies.
